Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| fibroblast | 12 studies | 32% ± 15% | |
| basal cell | 10 studies | 26% ± 11% | |
| club cell | 7 studies | 26% ± 6% | |
| secretory cell | 7 studies | 33% ± 12% | |
| adipocyte | 7 studies | 34% ± 20% | |
| respiratory goblet cell | 6 studies | 36% ± 17% | |
| epithelial cell | 5 studies | 26% ± 12% | |
| hepatocyte | 5 studies | 50% ± 27% | |
| endothelial cell | 4 studies | 31% ± 13% | |
| adventitial cell | 4 studies | 21% ± 4% | |
| endothelial cell of lymphatic vessel | 4 studies | 38% ± 26% | |
| duct epithelial cell | 3 studies | 38% ± 10% | |
| ciliated cell | 3 studies | 31% ± 11% |
Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| liver | 3 studies | 24% ± 4% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| liver | 100% | 14282.37 | 226 / 226 | 96% | 179.81 | 390 / 406 |
| kidney | 90% | 3121.57 | 80 / 89 | 68% | 40.82 | 610 / 901 |
| esophagus | 98% | 6404.93 | 1423 / 1445 | 57% | 120.77 | 104 / 183 |
| lung | 91% | 2278.94 | 524 / 578 | 60% | 155.17 | 692 / 1155 |
| bladder | 100% | 4747.67 | 21 / 21 | 38% | 40.58 | 190 / 504 |
| stomach | 96% | 7975.80 | 344 / 359 | 20% | 3.57 | 56 / 286 |
| breast | 96% | 7179.23 | 442 / 459 | 9% | 2.32 | 104 / 1118 |
| thymus | 97% | 3891.51 | 633 / 653 | 4% | 2.00 | 23 / 605 |
| ureter | 0% | 0 | 0 / 0 | 100% | 7.81 | 1 / 1 |
| adipose | 98% | 9277.60 | 1182 / 1204 | 0% | 0 | 0 / 0 |
| blood vessel | 93% | 3630.19 | 1237 / 1335 | 0% | 0 | 0 / 0 |
| skin | 86% | 3067.78 | 1558 / 1809 | 2% | 0.62 | 8 / 472 |
| pancreas | 42% | 751.55 | 138 / 328 | 40% | 7.31 | 72 / 178 |
| intestine | 70% | 1385.17 | 675 / 966 | 12% | 2.37 | 64 / 527 |
| heart | 82% | 4069.62 | 703 / 861 | 0% | 0 | 0 / 0 |
| muscle | 78% | 3839.22 | 626 / 803 | 0% | 0 | 0 / 0 |
| adrenal gland | 29% | 420.46 | 76 / 258 | 36% | 5.96 | 83 / 230 |
| prostate | 59% | 1176.64 | 144 / 245 | 3% | 0.65 | 15 / 502 |
| ovary | 53% | 814.17 | 96 / 180 | 1% | 0.14 | 6 / 430 |
| tonsil | 0% | 0 | 0 / 0 | 53% | 31.48 | 24 / 45 |
| uterus | 21% | 238.54 | 36 / 170 | 28% | 26.75 | 127 / 459 |
| brain | 19% | 248.43 | 492 / 2642 | 19% | 3.59 | 134 / 705 |
| peripheral blood | 2% | 81.67 | 22 / 929 | 0% | 0 | 0 / 0 |
| spleen | 2% | 28.75 | 5 / 241 | 0% | 0 | 0 / 0 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 80 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| lymph node | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 29 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| GO_0044597 | Biological process | daunorubicin metabolic process |
| GO_0006805 | Biological process | xenobiotic metabolic process |
| GO_0008206 | Biological process | bile acid metabolic process |
| GO_0030299 | Biological process | intestinal cholesterol absorption |
| GO_0071395 | Biological process | cellular response to jasmonic acid stimulus |
| GO_0044598 | Biological process | doxorubicin metabolic process |
| GO_0030855 | Biological process | epithelial cell differentiation |
| GO_0007586 | Biological process | digestion |
| GO_0042448 | Biological process | progesterone metabolic process |
| GO_0015721 | Biological process | bile acid and bile salt transport |
| GO_0001523 | Biological process | retinoid metabolic process |
| GO_0042574 | Biological process | retinal metabolic process |
| GO_2000379 | Biological process | positive regulation of reactive oxygen species metabolic process |
| GO_0006693 | Biological process | prostaglandin metabolic process |
| GO_0042632 | Biological process | cholesterol homeostasis |
| GO_0046683 | Biological process | response to organophosphorus |
| GO_0070062 | Cellular component | extracellular exosome |
| GO_0005829 | Cellular component | cytosol |
| GO_0047024 | Molecular function | 5alpha-androstane-3beta,17beta-diol dehydrogenase activity |
| GO_0047086 | Molecular function | ketosteroid monooxygenase activity |
| GO_0018636 | Molecular function | phenanthrene 9,10-monooxygenase activity |
| GO_0004032 | Molecular function | aldose reductase (NADPH) activity |
| GO_0016655 | Molecular function | oxidoreductase activity, acting on NAD(P)H, quinone or similar compound as acceptor |
| GO_0047006 | Molecular function | 17-alpha,20-alpha-dihydroxypregn-4-en-3-one dehydrogenase activity |
| GO_0047023 | Molecular function | androsterone dehydrogenase activity |
| GO_0047044 | Molecular function | androstan-3-alpha,17-beta-diol dehydrogenase activity |
| GO_0047718 | Molecular function | indanol dehydrogenase activity |
| GO_0004033 | Molecular function | aldo-keto reductase (NADPH) activity |
| GO_0033703 | Molecular function | 3beta-hydroxy-5beta-steroid dehydrogenase activity |
| GO_0032052 | Molecular function | bile acid binding |
| GO_0047042 | Molecular function | androsterone dehydrogenase (B-specific) activity |
| GO_0047045 | Molecular function | testosterone 17-beta-dehydrogenase (NADP+) activity |
| GO_0004303 | Molecular function | estradiol 17-beta-dehydrogenase [NAD(P)+] activity |
| GO_0030283 | Molecular function | testosterone dehydrogenase [NAD(P)+] activity |
| GO_0031406 | Molecular function | carboxylic acid binding |
| GO_0033764 | Molecular function | steroid dehydrogenase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor |
| GO_0035410 | Molecular function | dihydrotestosterone 17-beta-dehydrogenase activity |
| GO_0005515 | Molecular function | protein binding |
| GO_0047115 | Molecular function | trans-1,2-dihydrobenzene-1,2-diol dehydrogenase activity |
| Gene name | AKR1C1 |
| Protein name | Aldo-keto reductase family 1 member C1 (EC 1.1.1.-) (EC 1.1.1.112) (EC 1.1.1.209) (EC 1.1.1.210) (EC 1.1.1.357) (EC 1.1.1.51) (EC 1.1.1.53) (EC 1.1.1.62) (EC 1.3.1.20) (20-alpha-hydroxysteroid dehydrogenase) (20-alpha-HSD) (EC 1.1.1.149) (Chlordecone reductase homolog HAKRC) (Dihydrodiol dehydrogenase 1) (DD1) (High-affinity hepatic bile acid-binding protein) (HBAB) Aldo-keto reductase family 1 member C1 |
| Synonyms | DDH1 DDH |
| Description | FUNCTION: Cytosolic aldo-keto reductase that catalyzes the NADH and NADPH-dependent reduction of ketosteroids to hydroxysteroids . Most probably acts as a reductase in vivo since the oxidase activity measured in vitro is inhibited by physiological concentrations of NADPH . Displays a broad positional specificity acting on positions 3, 17 and 20 of steroids and regulates the metabolism of hormones like estrogens and androgens . May also reduce conjugated steroids such as 5alpha-dihydrotestosterone sulfate . Displays affinity for bile acids . . |
| Accessions | ENST00000380859.1 A6NHU4 H0Y804 Q04828 ENST00000442997.5 ENST00000380872.9 |